Advertisement

Topics

Pfizer’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment

19:00 EDT 3 Sep 2017 | Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval to Pfizer’s antibody-drug conjugate (ADC) Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with acute myeloid leukaemia (AML).

Original Article: Pfizer’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment

NEXT ARTICLE

More From BioPortfolio on "Pfizer’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...